Prosit Sole Biotechnology Initiates First-In-Human Clinical Trial of Novel Interferon Lambda Chimera in US

"Chronic norovirus enteritis in immunocompromised patients is an urgent unmet medical need. There are no approved therapies for this debilitating disease." said Hongyu Liu, PhD, CEO of Prosit Sole Biotechnology. "We are also actively developing PSP001 for additional indications such as chronic hepatitis B." "Chronic norovirus enteritis in immunocompromised patients is an urgent unmet medical need. There are no approved therapies for this debilitating disease." saidHongyu Liu, PhD, CEO of...

"Chronic norovirus enteritis in immunocompromised patients is an urgent unmet medical need. There are no approved therapies for this debilitating disease." said Hongyu Liu, PhD, CEO of Prosit Sole Biotechnology. "We are also actively developing PSP001 for additional indications such as chronic hepatitis B."

Investor Contact:

Email: [email protected]

Media Contact:

Cindy Yu
Email: [email protected]
010-62975234

Source: Prosit Sole Biotechnology

To learn more, please visit http://www.prositsole.com/